Precigen vs Royalty Pharma
Precigen (PGEN) and Royalty Pharma (RPRX) side by side: how big they are, what they earn, how their shares have moved and what insiders, members of Congress and funds reported. Figures from filings and closing prices; none of this is a view on either stock.
- Market value
- $1.51B
- Last close
- $4.21
- 12 months
- +8.0%
- Market value
- $39.4B
- Last close
- $68.45
- 12 months
- +78.3%
At a glance
- By market value, Royalty Pharma ($39.4B) is about 26 times Precigen ($1.5B).
- Over the last 12 months Precigen's share price moved +8.0% and Royalty Pharma's +78.3%; against the S&P 500 that is +2.2 points and +72.6 points.
- In their last fiscal years Precigen kept -2588.2% of revenue as net income and Royalty Pharma 32.4%.
- In the last 90 days insiders reported 0 open-market purchases at Precigen and 0 at Royalty Pharma; members of Congress disclosed 0 trades in Precigen and 0 in Royalty Pharma.
- Next results: Precigen not announced, Royalty Pharma Feb 9, 2027.
Share prices on one chart
Precigen and Royalty Pharma, and up to three more you add, drawn on the same scale so you can see which moved more.
Face to face
The figures that separate the two, drawn to the same scale. Every figure is also in the table below.
Size
Market value
Revenue, last fiscal year
Net income, last fiscal year
Every figure
| Precigen PGENNASDAQ · Pharmaceutical Preparations | Royalty Pharma RPRXNASDAQ · Pharmaceutical Preparations | |
|---|---|---|
| Size and profitability | ||
| Market value | $1.51B | $39.4B |
| Revenue, last fiscal year | $9.68M | $2.38B |
| Net income, last fiscal year | −$251M | $771M |
| Net marginNet income as a share of revenue | -2588.2% | 32.4% |
| Free cash flow | −$89.8M | |
Prices are end-of-day closes, and fundamentals are the companies' last annual figures from their SEC filings: a − or + in the table is a fact of the filing or the close, not a forecast. Market value is the company-level figure at the last close. Counts are of records OQRO holds, by their date; insider history since 2006 comes from the SEC's insider transactions data sets and every filing since. Planned sales under a 10b5-1 plan are counted like other sales.
Common questions
How is Precigen different from Royalty Pharma?
Precigen (PGEN) is in Pharmaceutical Preparations on NASDAQ, with $9.68M of revenue in its last fiscal year and a net margin of -2588.2%. Royalty Pharma (RPRX) is in Pharmaceutical Preparations on NASDAQ, with $2.38B of revenue in its last fiscal year and a net margin of 32.4%. Both are in the same industry, so the gap is mostly one of size and profitability. The table above sets their figures side by side; it compares filings and is not a view on either stock.
How do Precigen and Royalty Pharma compare in size?
Royalty Pharma has the larger market value: Precigen $1.51B and Royalty Pharma $39.4B, at the last close.
Whose share price rose more over the last 12 months, PGEN or RPRX?
Over the last 12 months Precigen moved +8.0% and Royalty Pharma +78.3%. Past price moves say nothing about the future.
Which has had more insider buying, Precigen or Royalty Pharma?
Since 2006, Precigen insiders reported 287 open-market purchases against 18 for Royalty Pharma. These are counts of what was filed, not a view on either stock.
Do members of Congress trade PGEN or RPRX?
In the last 12 months, members of Congress disclosed 0 trades in Precigen (PGEN) and 0 in Royalty Pharma (RPRX).
When did insiders last buy PGEN and RPRX?
See the record behind any of these
A free account opens the full history of every insider and company since 2006, the screener, alerts, Congress trades and fund moves.
Precigen pageRoyalty Pharma pageRare insider trades this weekAll comparisons
https://oqro.io/compare/pgen-vs-rprx

